Real-World Efficacy and Safety of Tofacitinib for Patients With Alopecia Areata: A Retrospective Multi-Center Cohort Study

    April 2026 in “ Clinical and Translational Science ”
    Yifan Jin, Juanmei Cao, Sai Yang … Ying Luo
    Studysummary In this multi-center, retrospective cohort study, researchers found that tofacitinib significantly reduced SALT scores and improved eyebrow and eyelash regrowth in patients with refractory alopecia areata after 12 weeks, with greater efficacy observed in severe cases and consistent results across pediatric and adult populations.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on doi.org →
    Discuss this study in the Community →

    Research cited in this study 16

    1. Significant Improvement With Ivarmacitinib After Suboptimal Response to Tofacitinib in Severe Alopecia Areata: A Case Report and Literature Review Frontiers in Immunology · 2026
    2. Sustaining Treatment Response in Alopecia Areata Through Tofacitinib Dose Tapering: A Single-Center Retrospective Study Journal of the American Academy of Dermatology · 2025
    3. Real-World Effectiveness and Safety of Tofacitinib for Alopecia Areata: A Retrospective Cohort Study of 202 Patients Australasian Journal of Dermatology · 2024
    4. Safety and Efficacy of Tofacitinib in 97 Alopecia Areata Patients Journal of cosmetic dermatology · 2024
    5. Long-Term Efficacy and Safety of Baricitinib in Patients With Severe Alopecia Areata: 104-Week Results From BRAVE-AA1 and BRAVE-AA2 Journal of the European Academy of Dermatology and Venereology · 2024
    6. Effectiveness and Predictive Factors of Response to Tofacitinib Therapy in 125 Patients with Alopecia Areata: A Single-Centre Real-World Retrospective Study Acta dermato-venereologica · 2023
    7. Drug Survival and Long-Term Outcome of Tofacitinib in Patients with Alopecia Areata: A Retrospective Study Acta dermato-venereologica · 2023
    8. Effectiveness of Tofacitinib in Pre-Adolescent Alopecia Areata: A Retrospective Case Series and Literature Review Acta dermato-venereologica · 2023
    9. Treatment of Moderate-to-Severe Alopecia Areata in Adolescents With Baricitinib: A Retrospective Review of 29 Patients Journal of The American Academy of Dermatology · 2023
    10. Alopecia Areata: Case Report and Review of Pathophysiology and Treatment with JAK Inhibitors Journal of autoimmunity · 2022
    11. Various Applications of Tofacitinib and Ruxolitinib in Dermatology and Rheumatology: A Review of Current Evidence and Future Perspective Dermatology practical & conceptual · 2022
    12. Oral Tofacitinib and Systemic Corticosteroids, Alone or in Combination, in Patients With Moderate-to-Severe Alopecia Areata: A Retrospective Study Frontiers in Medicine · 2022
    13. The Alopecia Areata Investigator Global Assessment Scale: A Measure for Evaluating Clinically Meaningful Success in Clinical Trials British Journal of Dermatology · 2020
    14. Tofacitinib for the Treatment of Severe Alopecia Areata and Variants: A Study of 90 Patients Journal of The American Academy of Dermatology · 2016
    15. Oral Ruxolitinib Induces Hair Regrowth in Patients with Moderate-to-Severe Alopecia Areata JCI insight · 2016
    16. Genome-Wide Association Study in Alopecia Areata Implicates Both Innate and Adaptive Immunity Nature · 2010